Topic: Day 3. DIA/NORD
For the venture capital, Mr Leff ( management director, Warburg Pincus ) indicated that there are much less interest in investing in new drugs for other diseases except in rare diseases as shown in a survey done last year. But there are hurdles such in the government regulatory agency need to overcome too.
With regard to the FDA rep. And the patient advocates involvement, (I presume in this case ,is represented by NORD ). But I have a different feeling about INDIVIDUAL patient advocate's usefulness in contribution to the actual process of drug approval.
Finally, most of the US presenters agree no matter who will become president next term, the most important for us, as an individual to do now is writing to our senators and congressman ,urging them work together to avoid the 8.5% overall budget cuts ACROSS the board starting Jan. 2nd, 2013.